Article Details

Prometheus Biosciences Announces FDA Acceptance of IND Application for PRA023 and ...

Retrieved on: 2020-12-16 16:52:30

Tags for this article:

Click the tags to see associated articles and topics

Prometheus Biosciences Announces FDA Acceptance of IND Application for PRA023 and .... View article details on hiswai:

Excerpt

PRA023, the company's lead product candidate, is a humanized IgG1 <b>monoclonal antibody</b> (mAb) that has been shown to block tumor necrosis factor ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up